Could a celery seed extract help prevent another stroke?

NCT ID NCT07230587

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether butylphthalide, a compound from celery seed, can improve long-term recovery in people who have had a minor ischemic stroke. 1,200 participants aged 40–80 will take either the drug or a placebo for 12 months. Researchers will measure survival, stroke recurrence, disability, new brain damage, and cognitive changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
butylphthalide (NBP), a compound from celery seed
What this could lead to
If it works, this could provide a new long-term treatment to reduce disability, prevent recurrent strokes, and protect cognitive function after a minor stroke.
What could go wrong
This is a large Phase 3 trial, but butylphthalide is not yet proven for long-term use in minor stroke. The benefits may be modest, and side effects are possible. Results may not apply to all stroke types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.